myelodysplastic syndrome
Conditions
Interventions
1:Cladribine combined with cytarabine
Sponsors
Shanghai Jiaotong University Affiliated Sixth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. MDS patients with IPSS score more than 1.0, including Intermediate-2 and high risk according to IPSS; 2. Aged 18 and 85 years; 3. Had received at least one kind of hypomethylating agents, including azacitidine or decitabine, achieved no response or relapsed after response. 4. ECOG score 0-2; 5. Creatinine <= 1.5 x ULN, BUN <= 1.5 x ULN, ALT<= 2 x ULN, AST<= 2 x ULN, Tbil<=1.5 x ULN; 6. The patient or family members understand and voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1. The liver and kidney functions were abnormal, which exceeded the standard of 1nclusion criteria. 2. Have a history of serious heart disease, including myocardial infarction, cardiac insufficiency grade 3-4; 3. Known HIV serological response is positive; Pregnant or lactating women; 4. There are other malignant tumors in the organs and have received any treatment for the tumors in the past three years. 5. Those who have participated in other clinical trials within one month; 6. Other researchers judged those who could not join the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survial; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate;Complete remission rate;Hematological improvement;Partial remission rate;Marrow complete remission; | — |
Countries
China
Contacts
Public ContactChunkang Chang
Shanghai Jiaotong University Affiliated Sixth People's Hospital
Outcome results
None listed